Aliskiren-Associated acute kidney injury in a patient with pre-existing chronic kidney disease and dilated cardiomyopathy

Clinical and Experimental Nephrology

Volumn 16, Issue 2, 2012, Pages 333-336

  Yamauchi, Junji ^a   Shibagaki, Yugo ^a   Uehara, Keita ^a   Yasuda, Takashi ^a   Kimura, Kenjiro ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE HOSPITAL   (Japan)

Author keywords

Aliskiren; Chronic kidney disease; Dilated cardiomyopathy; Normotensive ischemic acute kidney injury

Indexed keywords

ALISKIREN; BRAIN NATRIURETIC PEPTIDE; CARVEDILOL; CREATININE; ENALAPRIL; FUROSEMIDE; POTASSIUM; SPIRONOLACTONE;

ACUTE KIDNEY FAILURE; ADULT; APPETITE DISORDER; ARTICLE; CARDIAC RESYNCHRONIZATION THERAPY; CASE REPORT; CHRONIC KIDNEY DISEASE; CONGESTIVE CARDIOMYOPATHY; CREATININE BLOOD LEVEL; DEFIBRILLATION; DISEASE SEVERITY; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; ECHOCARDIOGRAPHY; HEART FAILURE; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; JAPANESE; KIDNEY FUNCTION; LABORATORY TEST; MALAISE; MALE; NORMOTENSIVE ISCHEMIC ACUTE KIDNEY INJURY; PATIENT MONITORING; POTASSIUM BLOOD LEVEL; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

ACUTE KIDNEY INJURY; ADULT; AMIDES; ANTIHYPERTENSIVE AGENTS; CARDIOMYOPATHY, DILATED; FUMARATES; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; NATRIURETIC PEPTIDE, BRAIN;

EID: 84863722055     PISSN: 13421751     EISSN: 14377799     Source Type: Journal    
DOI: 10.1007/s10157-011-0566-2     Document Type: Article

References (10)

1. Oparil S, Yarows SA, Patel S, Fang H, Zhang J, Satlin A. Efficacy and safety of combined use of aliskiren and valsartan in patients with hypertension: A randomized, double-blind trial. Lancet. 2007;370:221-9.
2. McMurray JJ, Pitt B, Latini R, Maggioni AP, Solomon SD, Keefe DL, et al. Effects of the oral direct renin inhibitor aliskiren in patients with symptomatic heart failure. Circ Heart Fail. 2008;1:17-24.
3. Parving HH, Persson F, Lewis JB, Lewis EJ, Hollenberg NK. Aliskiren combined with losartan in type 2 diabetes and nephropathy. N Engl J Med. 2008;358:2433-46.
4. Abuelo JG. Normotensive ischemic acute renal failure. N Engl J Med. 2007;357:797-805.
5. Ishani A, Xue JL, Himmelfarb J, Eggers PW, Kimmel PL, Molitoris BA, et al. Acute kidney injury increases risk of ESRD among elderly. J Am Soc Nephrol. 2009;20:223-8.
6. Kent DM, Jafar TH, Hayward RA, Tighiouart H, Landa M, de Jong P, et al. Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease. J Am Soc Nephrol. 2007;18:1959-65.
7. Fisher ND, Jan Danser AH, Nussberger J, Dole WP, Hollenberg NK. Renal and hormonal responses to direct renin inhibition with aliskiren in healthy humans. Circulation. 2008;117:3199-205.
8. Ito S, Nakura N, Breton SL, Keefe D. Efficacy and safety of aliskiren in Japanese hypertensive patients with renal dysfunction. Hypertens Res. 2010;33:62-6.
9. Venzin RM, Cohen CD, Maggiorini M, Wüthrich RP. Aliskirenassociated acute renal failure with hyperkalemia. Clin Nephrol. 2009;71:326-8.
10. Feldman DL, Persohn E, Schutz H, Miserendino-Molteni R, Xuan H, Zhuang S, et al. Renal localization of the renin inhibitor aliskiren. J Clin Hypertens. 2006;8:A80-1.